Earnings Call Summary | NexGel(NXGL.US) Q4 2023 Earnings Conference
Earnings Call Summary | NexGel(NXGL.US) Q4 2023 Earnings Conference
The following is a summary of the NEXGEL, Inc. (NXGL) Q4 2023 Earnings Call Transcript:
以下是NEXGEL, Inc.（NXGL）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
NEXGEL reported a nearly 100% revenue growth during 2023, amounting to approximately $4.1 million.
Gross margins for the year were 15.1%, up from 12.5% in 2022.
Q4 earnings from branded products reached $392,000, reflecting a 104.2% increase year-over-year and a 10.1% increase sequentially.
For Q1 2024, the company expects revenues of $1.25 million with similar or slightly improved margins.
The company's net loss for the year ending December 31, 2023, was $3.2 million, which is an improvement from a loss of $4.7 million in the same period in 2022.
NEXGEL報告稱，2023年收入增長了近100％，總額約爲410萬美元。
該年度的毛利率爲15.1％，高於2022年的12.5％。
第四季度品牌產品的收益達到39.2萬美元，同比增長104.2％，環比增長10.1％。
該公司預計2024年第一季度收入爲125萬美元，利潤率相似或略有提高。
截至2023年12月31日的財年，該公司的淨虧損爲320萬美元，較2022年同期的470萬美元虧損有所改善。
Business Progress:
業務進展：
In 2023, NEXGEL expanded its operation infrastructure, establishing strategic partnerships and making key investments.
The company achieved a significant growth driven by a 166% increase in contract manufacturing and 52% increase in branded products.
Major collaborations have been made, including an exclusive supply agreement deal with AbbVie and a partnership with European leader STADA.
The company acquired Kenkoderm, a skincare company, anticipating positive contributions to the financial results of Q1 2024.
To meet future growth demands, the company plans to expand facilities and increase operational efficiency.
The company invested and will continue to invest for European medical regulation compliance.
2023年，NEXGEL擴大了運營基礎設施，建立了戰略合作伙伴關係並進行了關鍵投資。
在合同製造增長166％和品牌產品增長52％的推動下，該公司實現了顯著增長。
已經進行了重大合作，包括與AbbVie的獨家供應協議以及與歐洲領導者STADA的合作伙伴關係。
該公司收購了護膚公司Kenkoderm，預計將對2024年第一季度的財務業績做出積極貢獻。
爲了滿足未來的增長需求，該公司計劃擴建設施並提高運營效率。
該公司已投資並將繼續投資以滿足歐洲醫療法規的合規性。
More details: NexGel IR
更多詳情： nexGel 紅外線
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。